about
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesDevelopment of a highly protective combination monoclonal antibody therapy against Chikungunya virusB cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within EndosomesHuman Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment StepComplement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile VirusImpact of Antigen Density on the Binding Mechanism of IgG AntibodiesHIV p24 as scaffold for presenting conformational HIV Env antigens.Influenza virus-specific neutralizing IgM antibodies persist for a lifetime.Immune mediators of rotavirus antigenemia clearance in mice.Serologic diagnosis of West Nile virus infection.Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals.Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particlesType I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection.IgM in microbial infections: taken for granted?Seroepidemiology of enterovirus D68 infection in China.Multiple Administrations of Viral Nanoparticles Alter in Vivo Behavior-Insights from Intravital Microscopy.The price of the CD27-CD70 costimulatory axis: you can't have it all.Unmutated immunoglobulin M can protect mice from death by influenza virus infection.Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.Etiology, pathogenesis, antivirals and vaccines of hand, foot, and mouth disease
P2860
Q24561905-CD00B0C5-D733-49BE-B2A9-867AD270A6F1Q27335008-E2A96AAF-624E-4EE9-A0BF-3AA53300ACE8Q27473103-0E5D6803-0214-4B39-BA1C-15E519318D1FQ27488367-FE54AE36-75B9-4203-8A5D-30C9AB0EFED8Q27488791-23F24F6C-46DC-41EE-AD1C-31DBFF37C1F8Q27490423-9863650C-0ADD-475F-AE7A-7E4741511B6EQ33812798-15F7B9FF-8FFA-465A-8535-CBE7EC245C10Q34389522-8CA297D4-0231-4094-99A2-C4DD0FBF7003Q34593000-29D123C2-3206-455D-86CA-1FB953966912Q35140279-CB03809D-0305-4AEF-AC48-64FF315F5F60Q35589295-43E3CE68-48FD-49D7-AE56-A21640AEA92FQ36424493-5CA70026-FC29-4122-B6C2-14C4EBB1AA9FQ36483436-24B5B32C-56EC-4B1A-A8A8-A19FE30BDB4EQ37033400-D313F0DB-865B-4F6B-867D-3CEF5D367496Q37107609-6F508DED-32BE-414F-90AB-B64FCB987164Q37251390-59804925-5EE5-4D4B-B224-8D115BEB0BD0Q37471226-AC1AE829-2FD4-4DF0-BD00-6C05EC471683Q37524875-5D47BE2A-E523-42F2-8AB3-15C8D70B935CQ40208346-ED8FF48A-A398-46D4-9359-97F38FF94DD5Q40765081-AAAC1750-A3EC-4C5B-924C-7ACA88A7899AQ41773141-8CD7CF89-6339-4967-8BDA-F596E9AB3C34Q41966856-8F3FBC20-C0A8-46D9-8430-59AEE4A1736DQ42227086-62E3E3BE-0C26-44F1-B199-E5646047925FQ42287446-672D846B-7AD8-41CB-93D9-3BB517F7D0FFQ55967992-33603307-4AF8-4A36-8BC4-4F504F96404F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Neutralizing antiviral antibody responses.
@ast
Neutralizing antiviral antibody responses.
@en
Neutralizing antiviral antibody responses.
@nl
type
label
Neutralizing antiviral antibody responses.
@ast
Neutralizing antiviral antibody responses.
@en
Neutralizing antiviral antibody responses.
@nl
prefLabel
Neutralizing antiviral antibody responses.
@ast
Neutralizing antiviral antibody responses.
@en
Neutralizing antiviral antibody responses.
@nl
P2093
P1476
Neutralizing antiviral antibody responses.
@en
P2093
Bachmann MF
Hengartner H
Hunziker L
Ochsenbein AF
Zinkernagel RM
P356
10.1016/S0065-2776(01)79001-3
P577
2001-01-01T00:00:00Z